Cialis: Tadalafil Brand Overview

Cialis Product Facts at a Glance

CIALIS is the proprietary product name for tadalafil tablets marketed under a U.S. New Drug Application. Tadalafil is the active pharmaceutical ingredient, while Cialis identifies the branded finished product with its own labeling, supplied strengths, appearance and product-specific instructions.

The current U.S. product context includes ED, BPH and combined ED/BPH. Initial U.S. approval was in 2003, and the current DailyMed listing identifies Eli Lilly and Company as the packager.

Cialis Is a Brand Product Containing Tadalafil

Tadalafil and Cialis describe two different levels of the same product relationship. Tadalafil is the nonproprietary name of the active drug, while Cialis is a proprietary finished-product name for tablets containing tadalafil.

That distinction matters because tadalafil is also available in FDA-approved generic products and in branded products with different indication contexts. A tadalafil tablet therefore should not automatically be called Cialis simply because it contains the same active molecule.

The broader drug-versus-brand terminology is covered on the tadalafil-Cialis identity page, allowing this page to stay focused on the characteristics of the CIALIS product itself.

What Is Cialis Approved to Treat?

Current U.S. CIALIS labeling includes three related indications: erectile dysfunction, the signs and symptoms of benign prostatic hyperplasia and treatment of men who have both ED and BPH. The same tadalafil molecule is used in each context, but the treatment objective and regimen framework are not identical.

For ED, tadalafil supports erectile response during sexual stimulation. In BPH, the labeled objective concerns signs and symptoms of benign prostatic hyperplasia, while the combined ED/BPH indication addresses both labeled conditions within a once-daily framework.

Condition-specific clinical context remains on tadalafil for BPH and tadalafil for ED and BPH.

Cialis Has Both As-Needed and Once-Daily Frameworks

The CIALIS label does not use one universal regimen for every indication. For as-needed ED treatment, the labeled starting framework for most patients is 10 mg before anticipated sexual activity, with adjustment to 5 mg or 20 mg according to efficacy and tolerability and a general maximum frequency of once per day.

For once-daily ED treatment, the label starts at 2.5 mg once daily and allows an increase to 5 mg. BPH and combined ED/BPH use a 5 mg once-daily framework taken at approximately the same time each day.

These figures describe the branded product label rather than individualized dose selection. Detailed interpretation, dose modifiers and regimen selection belong on the tadalafil dosage page and daily versus as-needed tadalafil.

Cialis Has a Specific Finasteride Context for BPH

Current labeling includes a defined role for CIALIS when BPH treatment is initiated together with finasteride. In that setting, the CIALIS component is 5 mg once daily and the combined initiation framework is recommended for up to 26 weeks.

The labeling limitation exists because the incremental benefit of CIALIS beyond 26 weeks in this combination context is not established. This is a specific product-label rule and should not be interpreted as a general statement about the duration of all BPH treatment.

Current Branded Cialis Strengths and Tablet Appearance

The current CIALIS How Supplied section lists branded tablets in 5 mg, 10 mg and 20 mg strengths. They are described as almond shaped, available in different sizes and shades of yellow and debossed with strength-specific CIALIS markings.

A useful distinction is that the current dosing section still describes 2.5 mg once daily as the starting framework for daily ED treatment even though 2.5 mg is not listed among the currently supplied branded CIALIS tablets in the present How Supplied section.

This difference illustrates why a dosing strength mentioned in prescribing instructions and a currently marketed branded package are not always the same question. Generic tadalafil products can also have supplied strengths and appearances that differ from branded Cialis.

Cialis Has a Long Tadalafil Pharmacokinetic Profile

The product's timing reputation is related in part to tadalafil pharmacokinetics. After a single oral dose, current labeling reports maximum observed plasma concentration between approximately 30 minutes and 6 hours, with a median Tmax of about 2 hours, while mean terminal half-life is approximately 17.5 hours in healthy subjects.

Those measurements describe drug concentration rather than exact clinical clocks. Tmax is not the same as the first possible erectile response, and half-life does not define a fixed number of hours during which every person will experience an effect.

For as-needed ED use, CIALIS clinical studies demonstrated improved erectile function compared with placebo at time points extending through 36 hours after dosing. Separate pages cover tadalafil onset, tadalafil duration and the full tadalafil pharmacokinetic profile.

How Cialis Fits the Tadalafil Mechanism

Cialis works through tadalafil's inhibition of phosphodiesterase type 5. In erectile tissue, PDE5 inhibition helps preserve cyclic GMP signaling generated after nitric oxide release during sexual stimulation, supporting smooth-muscle relaxation and increased penile blood flow.

The presence of tadalafil in the bloodstream does not itself create the intended erectile response without sexual stimulation, and CIALIS patient information does not describe the product as increasing sexual desire or curing the underlying cause of ED.

Mechanism is intentionally kept concise here because the molecular and physiologic pathway is covered in depth on how tadalafil works.

Cialis May Be Taken Without Regard to Food

Current CIALIS labeling states that the product may be taken without regard to food. Under the studied pharmacokinetic conditions, food does not meaningfully alter the rate or extent of tadalafil absorption.

That is a product-level administration fact rather than a claim that meals have no relevance to every practical aspect of sexual activity or treatment. The underlying absorption evidence is covered more fully on tadalafil food effects.

Key Cialis Safety Boundaries

Cialis shares tadalafil's systemic safety profile. Current labeling contraindicates use with organic nitrates and with guanylate cyclase stimulators such as riociguat because of potentially excessive blood-pressure lowering; serious hypersensitivity to tadalafil is also a contraindication.

The labeling additionally addresses cardiovascular suitability for sexual activity, prolonged erection or priapism, sudden vision loss, sudden hearing decrease or loss, blood-pressure effects with other vasodilating agents and clinically relevant drug interactions. An erection lasting more than four hours requires urgent medical attention.

This page intentionally keeps the safety section at product-overview level. Detailed interpretation belongs on tadalafil contraindications, tadalafil warnings and tadalafil drug interactions.

Common Adverse Reactions in the Cialis Label

Frequently reported adverse reactions in CIALIS clinical-trial labeling include headache, dyspepsia, back pain, myalgia, nasal congestion, flushing and pain in a limb. Reported frequencies vary by study, dose and regimen, so a brand overview is not the right place to collapse them into one universal percentage.

Back pain and myalgia have a recognized delayed pattern in tadalafil studies, but interpretation of frequency, severity and management belongs on the tadalafil side-effects page.

Kidney and Liver Function Can Change the Cialis Label Framework

Renal and hepatic impairment can change tadalafil exposure or the labeled way CIALIS is used. The restrictions differ between as-needed and once-daily treatment, so organ impairment should not be summarized as one universal dose adjustment.

For severe renal impairment or hemodialysis, the label restricts the as-needed framework and does not recommend once-daily CIALIS. Severe hepatic impairment is also a context in which use is not recommended, while mild or moderate impairment has regimen-specific cautions and limitations.

The detailed label distinctions belong on tadalafil and renal impairment and tadalafil and hepatic impairment.

Cialis Exists Alongside FDA-Approved Generic Tadalafil

Cialis is no longer the only U.S. tablet product supplying tadalafil for the relevant CIALIS reference-product context. FDA-approved generic tadalafil products are available, and products classified as therapeutically equivalent to the relevant reference product must satisfy FDA requirements that include pharmaceutical equivalence and bioequivalence.

Therapeutic equivalence does not require a generic tablet to copy every visible or inactive feature of branded Cialis. Manufacturer, excipients, tablet color, shape, imprint, packaging and price can differ even where the approved products are expected to provide the same clinical effect and safety profile under labeled conditions.

The generic-product concept is covered on generic tadalafil, while a direct finished-product comparison belongs on tadalafil vs Cialis. A wider catalog of product names belongs on tadalafil brand names.

Cialis Is Not the Same Product as Adcirca or TADLIQ

Cialis, Adcirca and TADLIQ all contain tadalafil, but they are separate finished products with different U.S. labeling contexts. CIALIS is labeled for ED, BPH and ED/BPH, while Adcirca and TADLIQ are tadalafil products used in the pulmonary arterial hypertension context.

Adcirca is a tablet product, whereas TADLIQ is an oral suspension. Sharing tadalafil as the active ingredient therefore does not make the products identical or make their dosing instructions interchangeable.

The most relevant brand-to-brand distinction is explored separately on Cialis vs Adcirca.

How to Identify the Current Branded Cialis Product

A prescription tablet should be identified through multiple product details rather than color alone. For branded CIALIS, useful identifiers include the product name, strength, tablet imprint, manufacturer or labeler and the dispensing or package information.

Current branded CIALIS tablets are almond shaped and the supplied 5 mg, 10 mg and 20 mg products carry the imprints C 5, C 10 and C 20 respectively. A generic tadalafil refill can legitimately look different because approved generic products do not have to reproduce every visual characteristic of the brand.

A change in tablet appearance therefore does not by itself prove that the active ingredient changed. When product identity matters, the pharmacy dispensing label and official product information are more reliable than resemblance to advertising images.

Common Misunderstandings About Cialis

Several common statements about Cialis mix together active-ingredient identity, pharmacokinetics and clinical response. Cialis contains tadalafil, but not every tadalafil product is Cialis; likewise, an FDA-approved generic that is therapeutically equivalent to the applicable CIALIS reference product is not inherently weaker simply because it lacks the Cialis brand name.

Timing concepts also need to remain separate. The approximately 36-hour response window does not describe a continuous erection, the approximately 17.5-hour terminal half-life is not an exact effect-duration clock and the approximately 2-hour median Tmax does not mean Cialis cannot produce a response before two hours.

Finally, Cialis is not only an ED brand. Its current U.S. labeling also includes BPH and combined ED/BPH indications.

Key Takeaways: Cialis

Cialis is a branded tadalafil tablet product with current U.S. indications for erectile dysfunction, BPH and combined ED/BPH. The currently supplied branded tablets are 5 mg, 10 mg and 20 mg, while the prescribing information still contains a 2.5 mg starting framework for once-daily ED treatment.

CIALIS supports both as-needed and once-daily treatment depending on indication. Its tadalafil pharmacokinetics contribute to a long exposure profile, while clinical evidence for as-needed ED use extends through a 36-hour post-dose response window without implying a continuous erection or fixed effect duration.

The Cialis name identifies a specific finished product rather than a different active drug from tadalafil. Generic tadalafil and other tadalafil brands exist, so active ingredient, indication, dosage form, therapeutic-equivalence context and product labeling should be distinguished rather than treating every tadalafil product as interchangeable in name or use.